Emraclidine (development code CVL-231) is a novel, brain-penetrant, highly selective muscarinic M4 receptor positive allosteric modulator (PAM). It is currently under development by Cerevel Therapeutics (now part of AbbVie) for the treatment of psychiatric and neurological disorders.
So, what makes Emraclidine different from typical antipsychotics?
Most antipsychotics work by blocking dopamine receptors — a mechanism that can cause significant side effects like movement disorders, weight gain, and metabolic issues. Emraclidine takes a completely different approach. As an M4 PAM, it doesn’t block receptors. Instead, it fine-tunes the activity of M4 receptors, which are highly expressed in brain regions implicated in schizophrenia, psychosis, and cognitive function. By selectively modulating these receptors, Emraclidine aims to achieve efficacy with a more favorable side effect profile — no dopamine blockade, no movement disorders, no weight gain.
At Cosperpharm, we produce Emraclidine API for research and development purposes, meeting ≥99% purity by HPLC. We hold a valid pharmaceutical export license, ensuring smooth customs clearance and complete documentation for your regulatory filings.
|
Parameter |
Specification |
|
CAS Number |
2170722-84-4 |
|
Molecular Formula |
C₂₀H₂₁F₃N₄O |
|
Molecular Weight |
390.40 g/mol |
|
Purity (HPLC) |
≥99% |
|
Any single impurity |
≤0.50% |
|
Total impurities |
≤1.0% |
|
Appearance |
White to off-white crystalline powder |
|
Storage |
-20°C (recommended for long-term) or 2-8°C, protected from light |
|
Packaging |
1g, 5g, 10g, 50g (customizable) |
The above specifications are a comprehensive reference version based on general standards of EMA (Europe) and FDA (USA).
|
Advantage |
Detail |
|
Production Strength |
GMP-certified campus spanning 100+ mu, 3 multi-purpose workshops, 6 D-grade clean zone production lines, and 150+ reactors (20L–5000L), supporting high/low temp, anaerobic & hydrogenation; kg to ton scale production |
|
Fast Delivery |
R&D samples: one week; commercial orders: 1-2 months after payment. Express (DHL/FedEx) or air/sea freight available |
|
Global Partners |
Trusted by 30+ pharmaceutical companies in USA, Europe, India, Brazil, and Southeast Asia; long-term cooperation with generic drug manufacturers and CROs |
|
Licensed Exporter |
Valid drug import/export license — no compliance delays. |
Unlike traditional antipsychotics that block dopamine D2 receptors, Emraclidine works as a positive allosteric modulator (PAM) of the muscarinic M4 receptor. But what does that actually mean?
`It fine-tunes, not blocks: Emraclidine binds to an allosteric site on the M4 receptor, enhancing the receptor’s response to its natural ligand (acetylcholine) without directly activating it.
`Better safety profile: Because it doesn’t block dopamine receptors, Emraclidine avoids common antipsychotic side effects such as extrapyramidal symptoms (movement disorders), tardive dyskinesia, weight gain, and metabolic syndrome.
`Brain-penetrant: Emraclidine is designed to cross the blood-brain barrier effectively, ensuring CNS target engagement at clinically relevant doses.
|
Feature |
Emraclidine (M4 PAM) |
Traditional Antipsychotics (e.g., Risperidone) |
|
Mechanism |
M4 receptor positive allosteric modulation |
Dopamine D2 receptor antagonism |
|
Side Effects |
No movement disorders, no weight gain, no metabolic issues |
EPS, tardive dyskinesia, weight gain, diabetes risk |
|
Target Selectivity |
High — M4-specific |
Low — broad dopamine blockade |
|
Patient Compliance |
Potentially higher due to better tolerability |
Often limited by side effects |
|
Approval Status |
Phase 2 clinical trials (investigational) |
Widely approved, multiple generics available |
Emraclidine is being developed by Cerevel Therapeutics (acquired by AbbVie in 2023 for approximately $8.7 billion). The drug has completed Phase 1b trials and advanced into Phase 2 clinical trials for the treatment of schizophrenia and psychosis in Alzheimer‘s disease.
`Study design: 112 patients with schizophrenia were randomized to receive once-daily Emraclidine (10mg, 30mg) or placebo for 6 weeks.
`Primary endpoint met: Both 10mg and 30mg doses demonstrated statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (p<0.01).
`Clean side effect profile: No significant differences in body weight, metabolic parameters, or movement disorder scales (EPS, akathisia) were observed between Emraclidine and placebo — a remarkable finding for an antipsychotic candidate.
`Good tolerability: Discontinuation rates were low, and most adverse events were mild to moderate.
`Best-in-Class Potential: Emraclidine is widely regarded as a potential best-in-class M4 PAM due to its high selectivity, brain penetration, and favorable clinical data.
`AbbVie‘s strategic bet: AbbVie’s acquisition of Cerevel for ~$8.7 billion in 2023 highlights Emraclidine‘s blockbuster potential in the CNS space.
`Unmet medical need: Schizophrenia affects approximately 24 million people worldwide, and current antipsychotics are limited by poor tolerability and significant side effects. A truly differentiated mechanism like Emraclidine could transform treatment paradigms.
`Patent protection: Key composition-of-matter patents extend through the early 2040s, ensuring long-term market exclusivity for innovators.
`Ongoing and planned Phase 2 trials for schizophrenia and Alzheimer‘s disease psychosis
`Data readouts expected in 2025-2026
`Phase 3 registration trials planned pending Phase 2 results
`First-in-class / Best-in-class M4 PAM mechanism — novel CNS target
`Clean side effect profile — no weight gain, no metabolic issues, no movement disorders (based on Phase 1b data)
`High M4 receptor selectivity — minimal off-target activity
`Brain-penetrant — effective CNS target engagement
`Backed by AbbVie’s $8.7B acquisition — validated potential
`Valid export license — Cosperpharm is an authorized API exporter
`Schizophrenia (primary target)
`Psychosis associated with Alzheimer’s disease
`Other cognitive and psychiatric disorders
Cosperpharm manufactures Emraclidine API for R&D purposes in modern GMP multi-purpose workshops equipped with 6 D-grade clean zone production lines. Our 150+ reactors (20L–5000L) support high/low temperature, anaerobic, and hydrogenation conditions, enabling production from kilogram to metric ton scale. Each batch undergoes rigorous QC testing: HPLC, GC, LC-MS, residual solvents (ICH Q3C), heavy metals, and genotoxic impurity analysis. We provide full traceability from raw material to finished API.
Q1: What is Emraclidine?
A: Emraclidine (CVL-231) is a novel, brain-penetrant, highly selective muscarinic M4 receptor positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer‘s disease psychosis. It represents a potentially best-in-class approach with a clean side effect profile.
Q2: How is Emraclidine different from existing antipsychotics?
A: Unlike traditional antipsychotics that block dopamine D2 receptors (causing weight gain, metabolic issues, and movement disorders), Emraclidine fine-tunes M4 receptor activity without dopamine blockade. Phase 1b data show no weight gain, no metabolic changes, and no EPS.
Q3: What is the current development stage of Emraclidine?
A: Emraclidine has completed Phase 1b trials and is currently in Phase 2 clinical trials for schizophrenia and Alzheimer’s disease psychosis. Phase 3 trials are planned pending Phase 2 results.
Q4: What is your MOQ for Emraclidine API?
A: R&D samples: 1g. Commercial R&D quantities: 5g–100g. Larger quantities available upon request.
Q5: What is your typical lead time?
A: In-stock R&D samples: one week. Bulk orders: 1-2 months after payment confirmation.
Q6: Which countries have you exported to?
A: USA, Canada, Germany, UK, Spain, India, Brazil, South Korea, Japan, and more. We have experience with local customs and regulatory requirements.
Q7: Can you provide third-party testing or audit?
A: Yes. We welcome customer audits or SGS/BV inspections. Third-party testing can be arranged at buyer‘s cost.
Q8: What certificates do you hold?
A: GMP certificate (ISO 9001:2015), pharmaceutical import/export license, and COA for each batch.
Q9: Do you offer customized packaging?
A: Yes. We can customize packaging size, labeling, and even inner lining materials per your request.
Ready to buy Emraclidine API for your CNS research? Contact Cosperpharm today for a sample or quote. We look forward to supporting your innovative drug development as a reliable China Emraclidine API supplier.
Address
No. 2 Yangguang 3rd Road, Duodao Chemical Cycle Industrial Park, Jingmen City, Hubei Province, China
Tel
